Direct acting antivirals for decompensated cirrhosis. Efficacy and safety are now established

Journal of Hepatology

Volumn 64, Issue 6, 2016, Pages 1206-1207

  Curry, Michael P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT; BILIRUBIN; DACLATASVIR; ENTECAVIR; LEDIPASVIR; NUCLEOSIDE ANALOG; RIBAVIRIN; SOFOSBUVIR;

ADVERSE OUTCOME; ANTIVIRAL THERAPY; BILIRUBIN BLOOD LEVEL; CHILD PUGH TURCOTTE SCORE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HOSPITALIZATION; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; TREATMENT OUTCOME; VIRAL CLEARANCE; CHRONIC HEPATITIS C; LIVER CIRRHOSIS;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS;

EID: 84961801655     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.02.041     Document Type: Editorial

References (13)

1. J. Serpaggi, and et al. Direct and indirect evidence for the reversibility of cirrhosis Hum Pathol 37 2006 1519 1526
2. T. Poynard, and et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
3. A.J. van der Meer, and et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
4. T.R. Morgan, and et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C Hepatology 52 2010 833 844
5. W.R. Kim, and et al. OPTN/SRTR 2013 Annual Data Report: liver Am J Transplant 15 2015 1 28
6. M. Charlton, and et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease Gastroenterology 149 2015 649 659
7. M.P. Curry, and et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis N Engl J Med 373 2015 2618 2628
8. F. Poordad, and et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence Hepatology 2016 10.1002/hep.28446 [Epub ahead of print]
9. M. Manns, and et al. Ledipasvir/Sofosbuvir with Ribavirin is safe and efficacious in decomensated and post-liver transplatation patients with HCV infection: preliminary results of the SOLAR-2 trial J Hepatol 62 2015 S187 S188
10. G.R. Foster, and et al. Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis J Hepatol 64 2016 1224 1231
11. Y. Nagaoki, and et al. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study J Gastroenterol Hepatol 2015 10.1111/jgh.13236 [Epub ahead of print]
12. A.S. Lok, and et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis Hepatology 63 2016 284 306
13. J.H. Shim, and et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis J Hepatol 52 2010 176 182